Status:
COMPLETED
PSMA-PET Imaging for Advanced ACC/SDC
Lead Sponsor:
Radboud University Medical Center
Collaborating Sponsors:
Adenoid Cystic Carcinoma Research Foundation
Conditions:
Salivary Gland Cancer
Adenoid Cystic Carcinoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Diagnostic study which evaluates the level of PSMA expression in patients with locally advanced, recurrent and/or metastatic ACC/SDC of ≥18 years old with 68Ga-PSMA-PET/CT imaging in order to establis...
Detailed Description
Rationale: PSMA is a transmembrane protein, which is expressed on prostate cancers cells, ACC and other malignancies. In prostate cancer, distant metastases can be visualized sensitively and non-invas...
Eligibility Criteria
Inclusion
- locally advanced, recurrent or metastatic ACC/SDC
- Age ≥ 18 years old
- Ability to provide written informed consent
Exclusion
- Contra-indication for PET imaging
- Pregnancy
- Breast feeding
- Severe claustrophobia
- Impaired renal function: MDRD \<30 ml/min/1,73 m2
- Impaired liver function: AST and ALT ≥ 2.5 x ULN (≥5 x ULN for patients with liver metastases)
Key Trial Info
Start Date :
October 25 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 14 2018
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT03319641
Start Date
October 25 2017
End Date
May 14 2018
Last Update
May 30 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Radboudumc
Nijmegen, Gelderland, Netherlands, 6500HB